Health Catalyst (HCAT) Set to Announce Quarterly Earnings on Wednesday

Health Catalyst (NASDAQ:HCAT) will announce its earnings results after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of $0.10 per share for the quarter. Health Catalyst has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Investors that wish to listen to the company’s conference call can do so using this link.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.04. The company had revenue of $75.90 million for the quarter, compared to analyst estimates of $74.96 million. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. Health Catalyst’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.21) EPS. On average, analysts expect Health Catalyst to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Health Catalyst Price Performance

Health Catalyst stock opened at $7.91 on Wednesday. The firm has a market capitalization of $478.32 million, a PE ratio of -4.28 and a beta of 1.32. The company’s 50-day moving average is $7.91 and its 200-day moving average is $7.02. Health Catalyst has a fifty-two week low of $5.42 and a fifty-two week high of $11.41.

Insider Buying and Selling at Health Catalyst

In other Health Catalyst news, COO Daniel Lesueur sold 8,137 shares of the business’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total value of $61,678.46. Following the completion of the sale, the chief operating officer now owns 140,108 shares of the company’s stock, valued at $1,062,018.64. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Health Catalyst news, insider Kevin Lee Freeman sold 7,500 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the sale, the insider now owns 255,881 shares of the company’s stock, valued at $1,847,460.82. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Daniel Lesueur sold 8,137 shares of the business’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $7.58, for a total transaction of $61,678.46. Following the completion of the sale, the chief operating officer now directly owns 140,108 shares of the company’s stock, valued at $1,062,018.64. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 35,396 shares of company stock valued at $258,415 in the last quarter. Company insiders own 2.70% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on HCAT shares. JPMorgan Chase & Co. boosted their price objective on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. Stephens lowered their price objective on shares of Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a report on Friday, October 4th. Piper Sandler reduced their target price on shares of Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a report on Monday, August 26th. Finally, Evercore ISI lifted their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Health Catalyst presently has an average rating of “Moderate Buy” and an average target price of $11.58.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.